SCOTTSDALE, AZ / ACCESSWIRE / February 19, 2016 / Avant Diagnostics, Inc. (OTCQB: AVDX), today announced that the company will present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at The Ritz-Carlton in Miami on South Beach on February 22, 2016
About Avant Diagnostics, Inc.
Avant is a medical diagnostic technology company that specializes in large panel biomarker tests. Our first test, OvaDx®, is proposed for use in monitoring women diagnosed previously with ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to ovarian tumor cell development. Pre-clinical research studies with OvaDx®indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510(k) clearance, Avant intends to sell or license OvaDx®. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.
About SeeThruEquity
Since the company's founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered and undercovered microcap stocks and hosting investor conferences throughout the year. STE has been able to grow its research universe to over 176 names.
STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because it augments the conference experience with the firm's research which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4500 attendees and have included over 1,700 1-on-1 meetings.
About The Brewer Group
The Brewer Group, Inc. (TBG) is an industry agnostic investment and consulting company with assets ranging numerous sectors. TBG's relationships with key international decision makers spanning government development agencies, financial institutions, multinational corporations, NGOs and numerous leaders in sports and entertainment place TBG in a unique position to grow its portfolio. TBG takes pride in identifying companies whose goal is to make a social impact on the communities in which they serve. For further information, please visit www.thebrewergroup.com.
Avant Diagnostics
Gregg Linn
President/CEO
602-524-4165
glinn@avantdiagnsotics.com
www.avantdiagnostics.com
Or
Goal Capital Inc., Investor Relations
Danny Gravelle
Tel 949-305-5093
contact@goalcapital.net
SOURCE: Avant Diagnostics, Inc.